 The China National Medical Products Administration has approved BeiGene Ltd NASDAQ: BGNE EUSA Pharma UK Ltds Sylvant siltuximab for adult patients with multicentric Castleman disease MCD, also known as idiopathic MCD iMCD. The approval covers patients who are human immunodeficiency virus HIV negative and human herpes virus-8 HHV-8 negative. 